NGEN-143 / NEUVOGEN - LARVOL DELTA

An optimized off-the-shelf whole tumor cell vaccine activates T cells that recognize a diverse antigen repertoire with potential to provide meaningful clinical benefit to patients with NSCLC (AACR 2025) - "In the CT26 model, vaccine monotherapy completely inhibited tumor growth (n=7/10) and mice were protected from rechallenge (n=7). Combination with αPD1 synergistically increased vaccine survival benefit.Our data demonstrate NGEN-143 has all the features to underpin clinical use in patients with NSCLC."

Clinical • IO biomarker • Tumor cell • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CASP3 • CCR7 • CD276 • CD40LG • CD8 • CSF2 • GZMB • IL12A • IL4 • TGFB1 • TGFB2 • TNFA

NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting (PRNewswire) - "Key Findings: In a fully human in vitro system, NGEN-143 expands effector T cells against a broad repertoire of both tumor-associated antigens and common shared neo-antigens across a wide range of HLA types....NGEN-143 activated T cells efficiently kill human tumor cells in a caspase-3 dependent manner. In the 'immune warm' CT26 mouse tumor model, vaccine abrogates or slows tumor growth – durable protection against rechallenge supports efficient induction of immune memory; vaccine + αPD1 improved survival over αPD1 monotherapy. In the 'immune cold' B16F10 mouse tumor model, our vaccine approach inhibits tumor growth and prolongs survival; vaccine + αPD1 improved survival."

Preclinical • Oncology